Evaluation of Intestinal Brush Border Enzyme Function in Critically Ill Patients
28 augusti 2017 uppdaterad av: Ulrike Holzinger, Medical University of Vienna
Evaluation of Intestinal Brush Border Enzyme Function in Patients With SIRS and Septic Shock Compared to Control Patients
The purpose of this study is to evaluate the role of several enzymes of the gut mucosa in preventing invasion of gastrointestinal bacteria.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Systemic Inflammatory Response Syndrome (SIRS), sepsis, septic shock and concomitant multiorgan failure are major causes of morbidity and mortality in intensive care units.
During SIRS and septic shock the role of the gut seems to be uncertain.
As it serves as an intestinal barrier which allows the symbiotic relationship between man and enteric bacteria, increased gut permeability during critical illness is accused to promote sepsis.
Brush border enzymes have the ability to detoxify lipopolysaccharides and prevent bacterial invasion across the gut mucosal barrier.
A reduced brush border enzyme function could contribute to the gastrointestinal intolerance in critically ill patients, which is frequently observed.
The aim of this study is to assess the influence of SIRS and septic shock on brush border enzyme morphology and function in men.
Studietyp
Interventionell
Inskrivning (Faktisk)
39
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Vienna, Österrike, 1090
- Medical University Vienna
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 80 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Septic Shock:
Recruitment and inclusion criteria
- 15 mechanically ventilated critically ill patients fulfilling criteria of SIRS (2 symptoms: RR > 20/min, HR > 90/min, Temp. > 38°/< 36°, 12G/l< WBC < 4G/l; assumed or proven infection, persistent hypotension refractory to fluid therapy and need for vasopressors.
- Time window for inclusion: up to 72h after onset of symptoms
Exclusion criteria
- PLT < 50G/l,
- PT < 50%,
- Continuous therapeutic anticoagulation,
- DIC, st. p. MCI within 14 days,
- Gastrointestinal perforation,
- Age < 18 years,
- Age > 80 Years
SIRS:
Recruitment and inclusion criteria
- 15 mechanically ventilated critically ill patients fulfilling criteria of SIRS (2 symptoms: RR > 20/min, HR > 90/min, Temp. > 38°/< 36°, 12G/l < WBC < 4G/l; assumed or proven infection
- Time window for inclusion: up to 72h after onset of symptoms
Exclusion criteria:
- PLT < 50G/l,
- PT < 50%, continuous therapeutic anticoagulation,
- DIC, st. p. MCI within 14 days,
- Gastrointestinal perforation,
- Age < 18 years,
- Age > 80 Years
Healthy/controls:
- 15 control subjects will be recruited from the outpatient ward referred to the endoscopy of the Department of Medicine III - Division of Gastroenterology and Hepatology for upper GI-endoscopy because of epigastric pain or reflux symptoms.
Inclusion criteria:
- Signed informed consent
Exclusion criteria:
- Patients with diarrhea of unknown origin, IBD or known celiac disease
- Age < 18 years
- Age > 80 Years
- PLT < 50G/l, PT < 50%
- Therapeutic oral anticoagulation
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Septic Shock
Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
|
When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
|
|
Övrig: SIRS
Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
|
When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
|
|
Övrig: healthy/controls
Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
|
When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
activity of the brush border membrane enzyme intestinal alkaline phosphatase
Tidsram: at inclusion
|
Duodenal biopsies will be taken on day 0 (at inclusion) and will be subsequently frozen.
Determination of enzyme activity will be done within 28 days.
|
at inclusion
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
activity of the brush border membrane enzyme maltase
Tidsram: at inclusion
|
Duodenal biopsies will be taken on day 0 (at inclusion) and will be subsequently frozen.
Determination of enzyme activity will be done within 28 days.
|
at inclusion
|
|
activity of the brush border membrane enzyme lactase
Tidsram: at inclusion
|
Duodenal biopsies will be taken on day 0 (at inclusion) and will be subsequently frozen.
Determination of enzyme activity will be done within 28 days.
|
at inclusion
|
|
Brush border morphology
Tidsram: at inclusion
|
Duodenal biopsies will be taken on day 0 (at inclusion) and will be subsequently frozen.
Determination of enzyme activity will be done within 28 days.
|
at inclusion
|
|
ICU mortality
Tidsram: at ICU discharge
|
only for groups "septic shock" and "SIRS"
|
at ICU discharge
|
|
hospital mortality
Tidsram: at hospital discharge
|
only for groups "septic shock" and "SIRS"
|
at hospital discharge
|
|
mortality (6 months)
Tidsram: 6 months after inclusion
|
6 months after inclusion
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Ulrike Holzinger, MD, Medical University of Vienna
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 juli 2011
Primärt slutförande (Faktisk)
1 februari 2015
Avslutad studie (Faktisk)
1 september 2015
Studieregistreringsdatum
Först inskickad
12 april 2012
Först inskickad som uppfyllde QC-kriterierna
24 april 2012
Första postat (Uppskatta)
26 april 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
29 augusti 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
28 augusti 2017
Senast verifierad
1 augusti 2017
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BBM_septic_shock
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .